健康妊娠与子痫前期母胎界面中的血管生成及血管活性蛋白
该研究在75对健康母婴与37对子痫前期母婴(含19例早发型和18例晚发型)剖宫产时采集母体桡动脉、子宫静脉、肘静脉及胎儿脐静脉、脐动脉血,用SomaScan检测胎盘生长因子、可溶性Fms样酪氨酸激酶1、可溶性内皮糖蛋白和内皮素1-3,描述其在母胎界面的分布及胎盘释放与摄取。
要点
- 子痫前期母体血管中可溶性Fms样酪氨酸激酶1和内皮素1丰度高于健康妊娠,早发型最高。
- 早发型子痫前期母体血管胎盘生长因子低于健康与晚发型子痫前期。
- 早发型子痫前期胎儿内皮素1和可溶性Fms样酪氨酸激酶1升高,可溶性内皮糖蛋白和内皮素3在两组子痫前期均低于健康对照。
核心结论
- 健康、晚发型子痫前期和早发型子痫前期三组间母体可溶性Fms样酪氨酸激酶1和内皮素1丰度递增并呈正相关,可能提示这些蛋白与疾病病理生理及严重程度相关。
- 早发型子痫前期胎儿循环内皮素1升高是一项新发现。
- 子痫前期蛋白丰度改变对胎儿发育和健康的长期影响仍未知,需进一步研究这些蛋白在病理生理及作为治疗靶点中的作用。
研究设计与样本
- 于计划剖宫产时采集75对健康母婴和37对子痫前期母婴(含19例早发型和18例晚发型)的母体桡动脉、子宫静脉、肘静脉及胎儿脐静脉、脐动脉血。
- 通过计算胎盘两侧静脉-动脉差值估计胎盘对蛋白的释放与摄取,采用基于微阵列的SomaScan检测法定量蛋白。
主要发现
- 子痫前期母体血管中可溶性Fms样酪氨酸激酶1和内皮素1丰度高于健康妊娠,早发型子痫前期丰度最高。
- 早发型子痫前期母体血管胎盘生长因子低于健康妊娠和晚发型子痫前期。
- 子痫前期母体内皮素2高于健康妊娠,晚发型子痫前期丰度最高。
- 模型证实所有组胎盘均向母体循环释放胎盘生长因子和可溶性Fms样酪氨酸激酶1,健康妊娠和晚发型子痫前期胎盘向胎儿循环释放可溶性Fms样酪氨酸激酶1。
- 早发型子痫前期胎儿内皮素1和可溶性Fms样酪氨酸激酶1较高,而可溶性内皮糖蛋白和内皮素3在两组子痫前期均低于健康对照。
临床怎么用
- 原文未据此给出推荐。
局限性
- 子痫前期蛋白丰度改变对胎儿发育和健康的长期影响仍未知。
- 需进一步研究这些蛋白在病理生理及作为治疗靶点中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preeclampsia is characterized by maternal endothelial activation and placental dysfunction. Imbalance in maternal angiogenic and vasoactive factors has been linked to the pathophysiology. The contribution of the placenta as a source of these factors remains unclear. Furthermore, little is known about fetal angiogenic and vasoactive proteins and the relation between maternal and fetal levels. OBJECTIVE: We describe placental growth factor, soluble Fms-like tyrosine kinase 1, soluble endoglin, and endothelin 1-3 in 5 vessels in healthy pregnancies, early- and late-onset preeclampsia. Specifically, we aimed to (1) compare protein abundance in vessels at the maternal-fetal interface between early- and late-onset preeclampsia, and healthy pregnancies, (2) describe placental uptake and release of proteins, and (3) describe protein abundance in the maternal vs fetal circulations. STUDY DESIGN: Samples were collected from the maternal radial artery, uterine vein and antecubital vein, and fetal umbilical vein and artery in 75 healthy and 37 preeclamptic mother-fetus pairs (including 19 early-onset preeclampsia and 18 late-onset preeclampsia), during scheduled cesarean delivery. This method allows estimation of placental release and uptake of proteins by calculation of venoarterial differences on each side of the placenta. The microarray-based SomaScan assay quantified the proteins. RESULTS: The abundance of soluble Fms-like tyrosine kinase 1 and endothelin 1 was higher in the maternal vessels in preeclampsia than in healthy pregnancies, with the highest abundance in early-onset preeclampsia. Placental growth factor was lower in the maternal vessels in early-onset preeclampsia than in both healthy and late-onset preeclampsia. Maternal endothelin 2 was higher in preeclampsia, with late-onset preeclampsia having the highest abundance. Our model confirmed placental release of placental growth factor and soluble Fms-like tyrosine kinase 1 to the maternal circulation in all groups. The placenta released soluble Fms-like tyrosine kinase 1 into the fetal circulation in healthy and late-onset preeclampsia pregnancies. Fetal endothelin 1 and soluble Fms-like tyrosine kinase 1 were higher in early-onset preeclampsia, whereas soluble endoglin and endothelin 3 were lower in both preeclampsia groups than healthy controls. Across groups, abundances of placental growth factor, soluble Fms-like tyrosine kinase 1, and endothelin 3 were higher in the maternal artery than the fetal umbilical vein, whereas endothelin 2 was lower. CONCLUSION: An increasing abundance of maternal soluble Fms-like tyrosine kinase 1 and endothelin 1 across the groups healthy, late-onset preeclampsia and early-onset combined with a positive correlation may suggest that these proteins are associated with the pathophysiology and severity of the disease. Elevated endothelin 1 in the fetal circulation in early-onset preeclampsia represents a novel finding. The long-term effects of altered protein abundance in preeclampsia on fetal development and health remain unknown. Further investigation of these proteins' involvement in the pathophysiology and as treatment targets is warranted.
引用
- Westerberg AC, Degnes ML, Andresen IJ, et al. Angiogenic and vasoactive proteins in the maternal-fetal interface in healthy pregnancies and preeclampsia. Am J Obstet Gynecol. 2024. PMID: 38494070. doi:10.1016/j.ajog.2024.03.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。